NCT05544032Approved For Marketing不适用
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantGraft-versus-host Disease (GVHD)NCT03147742Incyte Corporation
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company
Approved For Marketing
不适用
Margetuximab Expanded Access ProgramNCT03133988TerSera Therapeutics LLC
No Longer Available
不适用
Early Patient Access Treatment Use Protocol CA204-220Multiple MyelomaNCT02856438Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access Treatment Protocol CA204-143Multiple MyelomaNCT02368301Bristol-Myers Squibb